Search Results 491-500 of 16662 for Androgens

  1. Testing The Use Of Ado-Trastuzumab Emtansine Compared To The Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) For Recurrent, Metastatic, Or Unresectable HER2-Positive Salivary Gland Cancer - Mayo Clinic

    Note: Prior chemotherapy for a different cancer is allowed; prior androgen receptor targeted therapy in any setting is allowed; prior systemic therapy ...

  2. Medical Research & Education - Mayo Clinic News Network

    Mayo Clinic Platform_Accelerate graduation shows promise of health tech innovation for improving patient care. ROCHESTER, Minn.

  3. Alumni - Center for Clinical and Translational Science

    Leon Ferre, M.D., Unveiling the immune landscape of triple-negative breast cancer molecular subtypes, with emphasis on the luminal androgen receptor subtype ( ...

  4. Safety Of MT-401-OTS In Patients With Relapsed AML Or MDS - Mayo Clinic

    ... androgen-deprivation therapy 5. A malignancy that is considered cured with minimal risk of recurrence 8. Have any active systemic infection requiring ...

  5. Publications - Nahid Punjani, M.D., Dr.PH. - Mayo Clinic

    Androgens and COVID-19: exploring the role of testosterone replacement therapy. Int J Impot Res. 2022 Jan 30 [Epub ahead of print] View PubMed; Kang C ...

  6. Publications - Ayse Tuba Kendi, M.D. - Mayo Clinic

    Metastasis-directed Therapy Without Androgen Deprivation Therapy in Solitary Oligorecurrent Prostate Cancer. ... Radiographic paradoxical response in metastatic ...

  7. Investigating Magnesium Glycinate In Structure/Function Role Of Hot Flashes. - Mayo Clinic

    Androgens;; Systemic estrogens (topical vaginal estrogen OK);; Progestogens;; Tamoxifen, raloxifene and aromatase inhibitors are allowed, but patient must have ...

  8. Finasteride (oral route) - Side effects & dosage - Mayo Clinic

    Finasteride can cause birth defects in male babies. Finasteride is used to treat men who have symptoms of benign prostatic hyperplasia (BPH) and male pattern ...

  9. A Study To Evaluate The Safety, Pharmacokinetics, And Anti-tumor Activity Of LYT-200 Alone And Combined With Chemotherapy Or Tislelizumab To Treat Patients With Metastatic Solid Tumors - Mayo Clinic

    For Part 1, hormonal androgen deprivation therapy is allowed to continue for patients with metastatic castration-resistant prostate cancer. Any ablative ...

  10. Evaluating The Addition Of The Immunotherapy Drug Atezolizumab To Standard Chemotherapy Treatment For Advanced Or Metastatic Neuroendocrine Carcinomas That Originate Outside The Lung - Mayo Clinic

    exception of hormonal therapy including androgen deprivation therapy (e.g., gonadotropin-releasing hormone [GnRH] agonists or antagonists), which can be ...